Larry Nagahara, Ph.D.
Nanotechnology Projects Manager
National Cancer Institute
Grand Challenges for Nanomedicine and Nanobiology Workshop
August 27, 2007

• ~ 560,000 Americans will die of cancer this year
• ~1,300,000 Americans will hear the words “you have cancer…” this year
• ~$185 billion per year on healthcare costs – for cancer in the U.S. alone

We Must Accelerate Progress Against Cancer:
Early Diagnostics Is Key
Early Diagnostics Is Key

Understand the Causes and Mechanisms of Cancer
Accelerate Progress in Cancer Prevention
Improve Early Detection and Diagnosis
Develop Effective and Efficient Treatments
Understand the Factors that Influence Cancer Outcomes
Improve the Quality of Cancer Care
Improve the Quality of Life for Cancer Patients,
Survivors, and Their Families
Overcome Cancer Health Disparities

Nanotechnology is a “disruptive technology” which will drive a new generation of cancer diagnostic and therapeutic products, resulting in dramatically improved cancer outcomes

Early detection – highly sensitive and specific sensors

In-vivo imaging – new contrast agents, localization

Therapeutics – local, on-particle delivery
The Alliance was launched…

Detecting Cancer Early with
Targeted Nano-probes for
Vascular Signatures, University of California, San Francisco, Calif.
Nanosystem s Biology
Cancer
Center,
California
Institute of
Technology,
Pasadena,
Calif.
Nanotechnology Platform for
Pediatric Brain Cancer Imaging
and Therapy, University of
Washington, Seattle, Wash.
Center for Cancer Nanotechnology
Excellence Focused on Therapy Response,
Stanford University, Palo Alto, Calif.
Center of Nanotechnology for
Treatment, Understanding, and
Monitoring of Cancer, University of
California, San Diego, Calif.
Nanotechnology Platform for
Targeting Solid Tumors, The
Sidney Kimmel Cancer Center,
San Diego, Calif.
Centers of Cancer Nanotechnology
Excellence (8)
Cancer Nanotechnology Platform
Partnerships (12)
Novel Cancer Nanotechnology Platforms for
Photodynamic Therapy and Imaging, Roswell Park
Cancer Institute, Buffalo, N.Y.
Multifunctional Nanoparticles in Diagnosis and
Therapy of Pancreatic Cancer, State University of New
York, Buffalo, N.Y.
Integrated System for Cancer
Biomarker Detection,
Massachusetts Institute of
Technology, Cambridge, Mass.
MIT-Harvard Center of Cancer
Nanotechnology Excellence,
Cambridge, Mass.
DNA-linked Dendrimer Nanoparticle Systems for
Cancer Diagnosis and Treatment, University of
Michigan, Ann Arbor, Mich.
Nanomaterials for Cancer
Diagnostics and Therapeutics,
Northwestern University, Evanston, Ill.
Hybrid Nanoparticles in
Imaging and Therapy of
Prostate Cancer, University of
Missouri, Columbia, Mo.
Metallofullerene
Nanoplatform for
Imaging and Treating
Infiltrative Tumor,
Virginia Commonwealth
University, Richmond, Va.
The Siteman Center of Cancer
Nanotechnology Excellence at
Washington University, St. Louis, Mo.
Near-Infrared Fluorescence
Nanoparticles for Targeted
Optical Imaging
University of Texas M. D.
Anderson Cancer Center,
Houston, Texas
Emory-Georgia Tech Nanotechnology Center for Personalized
and Predictive Oncology,
Atlanta, Ga.
Carolina Center of Cancer
Nanotechnolog y Excellence,
University of
North Carolina,
Chapel Hill, N.C.
Nanotherapeutic
Strategy for
Multidrug
Resistant Tumors,
Northeastern
University, Boston,
Mass.
Photodestruction of Ovarian Cancer:
ErbB3 Targeted
Aptamer-
Nanoparticle
Conjugate,
Massachusetts
General Hospital,
Boston, Mass.
$145 Million/5 Years
(2005-2010)

Focus Areas:
• Molecular imaging and early detection
• In vivo imaging
• Reporters of efficacy
• Multifunctional therapeutics
• Prevention and control
• Research enablers
Early detection Imaging Therapy

protrusion adhesion traction deadhesion
• What are the nanomechanics involved in making a cancer cells move?
Milan Mrksich - NWU NWU CCNE

• CHECK IT OUT!!!
Piotr Grodzinski, Ph.D.
Program Director
Email: grodzinp@mail.nih.gov
Larry Nagahara, Ph.D.
Nanotechnology Projects Manager
Email: nagaharl@mail.nih.gov
Jerry Lee, Ph.D.
Nanotechnology Projects Manager
Email: leejerry@mail.nih.gov
Office of the Director
National Cancer Institute
31 Center Drive
MSC 2580 Rm. 10A52
Bethesda, MD 20892-2580
Phone: (301) 496-1550
Fax: (301) 496-7807

The National Cancer Institute (NCI) is interested in:
1.
Early detection of the disease using imaging
2.
In vitro early diagnostics: multiplexed sensitive and specific sensors
3.
Multi-functional therapeutics and localized therapy delivery
4.
Tools and approaches to interrogate, understand, and manipulate single cells, structures, and molecules
NIH/CDC Small Business Innovation Research (SBIR) Contract Solicitation
Contract proposal receipt date: NOVEMBER 5, 2007
241 Multifunctional Therapeutics Based on Nanotechnology
252 Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer